Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

FGEN

FibroGen Inc

May 16 • 12:35PM ET

1.18

Dollar change -0.01
Percentage change -0.42	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO VHT FESM VTWV IWV BTEC

Index	RUT	P/E	-	EPS (ttm)	-2.45	Insider Own	6.90%	Shs Outstand	98.77M	Perf Week	-2.87%
Market Cap	117.88M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.73%	Shs Float	92.61M	Perf Month	-6.69%
Income	-240.46M	PEG	-	EPS next Q	-0.32	Inst Own	67.17%	Short Float	7.47%	Perf Quarter	-44.88%
Sales	167.49M	P/S	0.70	EPS this Y	55.25%	Inst Trans	2.87%	Short Ratio	3.09	Perf Half Y	146.46%
Book/sh	-2.29	P/B	-	EPS next Y	56.12%	ROA	-53.17%	Short Interest	6.92M	Perf Year	-93.24%
Cash/sh	1.79	P/C	0.66	EPS next 5Y	-	ROE	-42790.17%	52W Range	0.33 - 19.47	Perf YTD	33.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-93.91%	Beta	0.82
Dividend TTM	-	Quick Ratio	1.27	Sales past 5Y	-2.51%	Gross Margin	75.46%	52W Low	255.54%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	1.41	EPS Y/Y TTM	25.09%	Oper. Margin	-133.85%	RSI (14)	44.42	Volatility	11.28% 13.42%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	44.30%	Profit Margin	-143.56%	Recom	4.00	Target Price	1.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.93%	Payout	-	Rel Volume	0.62	Prev Close	1.19
Sales Surprise	52.47%	EPS Surprise	21.05%	Sales Q/Q	54.59%	Earnings	May 06 AMC	Avg Volume	2.24M	Price	1.18
SMA20	3.75%	SMA50	-26.20%	SMA200	0.01%	Trades		Volume	694,821	Change	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	Loading…
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
07:00AM	Loading…
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
05:33PM	Loading…
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
May-18-23 07:30AM	FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia (GlobeNewswire)
May-09-23 10:22AM	Q1 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:12PM	FibroGen: Q1 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports First Quarter 2023 Financial Results (GlobeNewswire)
04:00PM	FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics (GlobeNewswire)
May-05-23 01:19PM	FibroGen, Inc. (NASDAQ:FGEN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
07:37AM	FibroGen's anemia drug fails to meet main goal in late-stage trial (Reuters)
07:30AM	FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) (GlobeNewswire)
May-03-23 03:43AM	ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains? (Zacks)
May-01-23 07:00AM	FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value (GlobeNewswire)
Apr-24-23 07:00AM	FibroGen to Report First Quarter 2023 Financial Results (GlobeNewswire) -17.21%
Apr-03-23 07:00AM	FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-24-23 10:21AM	FibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past week (Simply Wall St.)
Mar-11-23 03:27AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-28-23 02:43PM	Q4 2022 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:25PM	FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
07:00AM	FibroGen to Present at Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-23-23 11:33AM	Should You Buy FibroGen (FGEN) Ahead of Earnings? (Zacks)
07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-22-23 10:00AM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-20-23 10:00AM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-17-23 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	FibroGen to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-16-23 09:34AM	With 73% ownership in FibroGen, Inc. (NASDAQ:FGEN), institutional investors have a lot riding on the business (Simply Wall St.)
Nov-28-22 07:00AM	FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference (GlobeNewswire)
Nov-09-22 05:15AM	FibroGen Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +6.78%
Nov-07-22 05:45PM	FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Third Quarter 2022 Financial Results (GlobeNewswire)
04:00PM	FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management (GlobeNewswire)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wettig Thane	CEO	Mar 07 '24	Buy	1.91	50,000	95,470	470,178	Mar 11 07:06 PM
Henderson Jeffrey William	Director	Sep 01 '23	Sale	1.03	2,000	2,060	28,866	Sep 06 08:54 PM
Henderson Jeffrey William	Director	Aug 04 '23	Sale	1.91	2,000	3,820	30,866	Aug 08 07:10 PM
Henderson Jeffrey William	Director	Jul 11 '23	Sale	2.69	2,000	5,380	32,866	Jul 13 08:28 PM
Conterno Enrique A	Chief Executive Officer	Jul 07 '23	Sale	2.80	1,880	5,264	374,722	Jul 10 07:36 PM
Wettig Thane	Chief Commercial Officer	Jun 23 '23	Sale	16.53	791	13,075	108,261	Jun 26 04:27 PM
Chung Christine	SVP, China Operations	Jun 14 '23	Sale	16.79	6,250	104,925	236,327	Jun 15 08:17 PM
Chung Christine	SVP, China Operations	Jun 13 '23	Sale	17.60	6,250	110,000	242,577	Jun 15 08:17 PM
Blaug Suzanne	Director	Jun 09 '23	Sale	17.20	8,520	146,571	29,594	Jun 09 07:54 PM
EDWARDS JEFFREY L	Director	Jun 09 '23	Sale	17.19	7,889	135,622	33,977	Jun 09 07:53 PM
Brennan Aoife	Director	Jun 09 '23	Sale	17.19	4,733	81,367	27,947	Jun 09 07:55 PM
Cravatt Benjamin	Director	Jun 09 '23	Sale	17.17	3,944	67,717	28,736	Jun 09 07:56 PM
Ho Maykin	Director	Jun 08 '23	Sale	17.44	8,520	148,591	31,501	Jun 09 07:54 PM
Henderson Jeffrey William	Director	Jun 08 '23	Sale	17.46	7,000	122,185	34,866	Jun 09 07:52 PM
Conterno Enrique A	Chief Executive Officer	Jun 07 '23	Sale	17.04	8,897	151,583	376,602	Jun 09 07:10 PM
Schoeneck James A	Director	Jun 07 '23	Sale	18.03	7,100	127,987	73,722	Jun 09 07:51 PM
Chung Christine	SVP, China Operations	Jun 07 '23	Sale	17.04	3,633	61,894	248,827	Jun 09 07:38 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 07 '23	Sale	17.04	2,042	34,792	162,862	Jun 09 07:12 PM
Graham Juan	Chief Financial Officer	Jun 07 '23	Sale	16.99	1,785	30,320	71,083	Jun 09 07:39 PM
Wettig Thane	Chief Commercial Officer	Jun 07 '23	Sale	17.04	1,758	29,951	111,395	Jun 09 07:39 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 02 '23	Sale	18.83	1,090	20,525	164,904	Jun 05 04:22 PM

Open in Screener

SYBX

Synlogic Inc

May 16 • 12:33PM ET

1.73

Dollar change +0.00
Percentage change 0.29	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-10.09	Insider Own	42.67%	Shs Outstand	9.19M	Perf Week	-5.74%
Market Cap	20.06M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	-0.01%	Shs Float	6.67M	Perf Month	-2.54%
Income	-73.22M	PEG	-	EPS next Q	-0.36	Inst Own	43.80%	Short Float	0.36%	Perf Quarter	-6.25%
Sales	3.21M	P/S	6.25	EPS this Y	71.85%	Inst Trans	-12.95%	Short Ratio	0.59	Perf Half Y	-18.63%
Book/sh	1.15	P/B	1.51	EPS next Y	94.76%	ROA	-113.09%	Short Interest	0.02M	Perf Year	-78.67%
Cash/sh	2.78	P/C	0.62	EPS next 5Y	-	ROE	-178.51%	52W Range	1.55 - 9.90	Perf YTD	-55.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.95%	ROI	-291.53%	52W High	-82.58%	Beta	1.02
Dividend TTM	-	Quick Ratio	3.19	Sales past 5Y	57.51%	Gross Margin	-62.40%	52W Low	11.29%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	3.19	EPS Y/Y TTM	27.68%	Oper. Margin	-1543.65%	RSI (14)	37.97	Volatility	4.02% 4.66%
Employees	6	Debt/Eq	1.09	Sales Y/Y TTM	188.74%	Profit Margin	-2284.68%	Recom	3.00	Target Price	1.00
Option/Short	No / Yes	LT Debt/Eq	0.89	EPS Q/Q	23.31%	Payout	-	Rel Volume	0.11	Prev Close	1.72
Sales Surprise	-	EPS Surprise	-217.07%	Sales Q/Q	-95.40%	Earnings	May 14 BMO	Avg Volume	41.08K	Price	1.73
SMA20	-6.06%	SMA50	-4.88%	SMA200	-47.67%	Trades		Volume	2,242	Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-21	Upgrade	Oppenheimer	Perform → Outperform	$7
Aug-21-19	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-19	Initiated	Jefferies	Buy	$18
Dec-13-18	Initiated	Chardan Capital Markets	Buy	$20
Mar-19-18	Initiated	H.C. Wainwright	Buy	$20
Jan-29-18	Initiated	Piper Jaffray	Overweight	$16

May-14-24 01:54PM	SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Synlogic Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-19-24 08:10AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.32%
07:00AM	Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-20-24 12:15PM	Synlogic Adopts Limited Duration Stockholders Rights Plan (GlobeNewswire)
09:41AM	Loading…
Feb-09-24 09:41AM	PayPal downgraded, United Airlines upgraded: Wall Street's top analyst calls (The Fly) -48.70%
08:42AM	Why Is Synlogic (SYBX) Stock Down 55% Today? (InvestorPlace)
05:47AM	Synlogic reaches end of line, laying off 90% of staff and ceasing operations after phase 3 fail (FierceBiotech.com)
Feb-08-24 04:15PM	Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update (GlobeNewswire)
Feb-02-24 12:00PM	Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria (GlobeNewswire)
Jan-16-24 08:47AM	Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) -6.08%
Jan-04-24 07:00AM	Synlogic Provides Corporate Update and Outlook for 2024 (GlobeNewswire)
Dec-27-23 07:00AM	Synlogic Announces Contract with the Air Force Research Lab (GlobeNewswire) -7.24%
Dec-07-23 07:00AM	Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 (GlobeNewswire) +11.60%
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE) +17.78%
07:19AM	Loading…
Nov-09-23 07:19AM	Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ... (GuruFocus.com) -15.02%
07:00AM	Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 07:00AM	Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration (GlobeNewswire)
Nov-02-23 10:00AM	Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-03-23 04:15PM	Synlogic Announces Closing of $21.0 Million Underwritten Public Offering (GlobeNewswire) -7.72%
Sep-29-23 07:00AM	Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering (GlobeNewswire) -11.08%
Sep-28-23 11:15AM	Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism (GlobeNewswire) -24.49%
09:13AM	Why Is Synlogic (SYBX) Stock Down 6% Today? (InvestorPlace)
Sep-27-23 12:30PM	Synlogic Announces Reverse Stock Split (GlobeNewswire) -15.48%
Sep-21-23 07:00AM	Synlogic to Participate in Chardans Genetic Medicines Conference (GlobeNewswire)
Sep-19-23 11:00AM	Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 (GlobeNewswire) -21.79%
Aug-10-23 08:40AM	Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 07:00AM	Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria (GlobeNewswire) +5.49%
Jun-28-23 07:00AM	Synlogic Announces International Nonproprietary Name Selection for SYNB1934 (GlobeNewswire) -9.78%
07:00AM	Loading…
Jun-27-23 07:00AM	Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum (GlobeNewswire) +15.68%
Jun-08-23 06:45AM	Synlogic Reminds Stockholders of 2023 Annual General Meeting Details (GlobeNewswire)
Jun-05-23 06:45AM	Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria (GlobeNewswire) -14.65%
May-24-23 06:35AM	Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference (GlobeNewswire)
May-23-23 06:50AM	Synlogic to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-23 08:21AM	Synlogic First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
08:05AM	Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -10.36%
06:50AM	Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria (GlobeNewswire)
May-04-23 10:00AM	Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-28-23 05:12PM	3 Megatrend Stocks to Buy for 10x Potential Returns (InvestorPlace)
Mar-29-23 07:55AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
06:40AM	Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire)
Mar-28-23 06:52AM	Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria (GlobeNewswire) +5.32%
Mar-20-23 06:55AM	Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (GlobeNewswire) +7.81%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -10.37%
Mar-08-23 07:00AM	Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
06:57AM	Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (GlobeNewswire)
Jan-24-23 06:57AM	Synlogic Announces Participation in Upcoming Investor and Industry Conferences (GlobeNewswire)
Jan-19-23 06:58AM	Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU) (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-16-23 12:00PM	Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why (Zacks)
Jan-14-23 07:17AM	Even after rising 15% this past week, Synlogic (NASDAQ:SYBX) shareholders are still down 90% over the past five years (Simply Wall St.)
Jan-05-23 06:58AM	Synlogic Provides Corporate Update and Outlook for 2023 (GlobeNewswire) +11.33%
Jan-03-23 06:58AM	Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development (GlobeNewswire)
Dec-15-22 10:49AM	Synlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients (Benzinga) +8.28%
06:59AM	Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study (GlobeNewswire)
Dec-04-22 09:27AM	Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 04:15PM	Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update (GlobeNewswire)
Nov-10-22 08:05AM	Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.88%
06:59AM	Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-18-22 11:15AM	Synlogic Touts Positive Data From Rare Inherited Disorder Trial, Pivotal Study To Start Next Year (Benzinga)
06:59AM	Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3 (GlobeNewswire)
Sep-06-22 07:00AM	Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease (GlobeNewswire)
Aug-23-22 07:00AM	Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU) (GlobeNewswire)
Aug-11-22 03:50PM	Ginkgo Bioworks partners with Synlogic on new gout drug (Yahoo Finance Video) +11.22%
08:15AM	Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks (PR Newswire)
06:58AM	Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-22 07:00AM	Synlogic Announces Second Quarter 2022 Conference Call and Webcast (GlobeNewswire) -7.58%
Jul-12-22 07:00AM	Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) (GlobeNewswire)
Jun-29-22 07:00AM	Synlogic Announces Appointment of General Counsel and Corporate Secretary (GlobeNewswire)
Jun-28-22 07:00AM	Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference (GlobeNewswire) -6.19%
Jun-27-22 10:06AM	Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-21-22 07:00AM	Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference (GlobeNewswire) +9.62%
Jun-01-22 07:00AM	Synlogic Reminds Stockholders of 2022 Annual General Meeting Details (GlobeNewswire)
May-24-22 07:00AM	Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria (GlobeNewswire) -7.44%
May-12-22 10:51AM	Synlogic (NASDAQ:SYBX shareholders incur further losses as stock declines 28% this week, taking three-year losses to 85% (Simply Wall St.) -14.40%
08:35AM	Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 07:00AM	Synlogic Announces First Quarter 2022 Conference Call and Webcast (GlobeNewswire) -6.36%
Apr-28-22 07:00AM	Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium (GlobeNewswire)
Apr-26-22 07:00AM	Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference (GlobeNewswire)
Apr-01-22 07:00AM	Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting (GlobeNewswire)
Mar-17-22 08:25AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 07:00AM	Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast (GlobeNewswire)
Mar-03-22 07:00AM	Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer (GlobeNewswire)
Feb-24-22 07:00AM	Synlogic To Present at Upcoming Investor and Industry Conferences (GlobeNewswire)
Feb-08-22 07:00AM	Synlogic To Present at Upcoming Investor and Industry Conferences (GlobeNewswire)
Jan-11-22 08:59AM	Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely? (Simply Wall St.)
Jan-06-22 07:00AM	Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences (GlobeNewswire)
Dec-24-21 12:00PM	What Makes Synlogic, Inc. (SYBX) a New Buy Stock (Zacks)
Nov-30-21 10:54AM	These 2 Penny Stocks Are Set for Massive Gains, Says Oppenheimer (TipRanks)
Nov-22-21 07:45PM	Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618 (PR Newswire) -6.08%
Nov-18-21 01:04PM	AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU (Zacks) -6.34%
12:58PM	Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU (Zacks)

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Awad Antoine	Chief Operating Officer	Apr 02 '24	Sale	1.73	372	644	33,859	Apr 04 04:00 PM
Dooley Mary Beth	Head of Finance	Apr 02 '24	Sale	1.73	188	325	15,231	Apr 04 04:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

FGEN

FibroGen Inc

SYBX

Synlogic Inc

Upgrade your FINVIZ experience